Skip to main content
. Author manuscript; available in PMC: 2024 Apr 17.
Published in final edited form as: Lancet. 2023 Apr 15;401(10384):1277–1292. doi: 10.1016/S0140-6736(23)00285-4

Figure 5: 10-year cumulative risk of recurrence with concurrent anthracycline plus docetaxel plus cyclophosphamide versus same dose docetaxel plus cyclophosphamide, by oestrogen receptor and nodal status.

Figure 5:

10-year risk of any recurrence in 836 patients on concurrent anthracycline plus docetaxel plus cyclophosphamide (n=417) versus same dose docetaxel plus cyclophosphamide (n=419) who were ER-negative (A) and 1633 patients (819 vs 814) who were ER-positive (B), both smoothed after 5 years (dotted line), and in 885 patients (432 vs 453) with node-negative cancer (C) and 1584 patients (804 vs 780) with node-positive cancer (D), both smoothed after 4 years (dotted line). Error bars show 95% CI. ER=oestrogen receptor. O–E=observed minus expected. RR=rate ratio. V=variance. 2p=two-sided p value.